Format

Send to

Choose Destination
See comment in PubMed Commons below
Invest Ophthalmol Vis Sci. 2003 Feb;44(2):740-4.

Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate.

Author information

1
Department of Ophthalmology, Nagoya City University Medical School, Nagoya, Japan.

Abstract

PURPOSE:

To evaluate the feasibility of using a biodegradable intrascleral implant for intraocular sustained delivery of betamethasone phosphate (BP).

METHODS:

The intrascleral implant (0.5 mm thick and 4 mm in diameter) was made of poly(DL-lactide) containing 25% betamethasone phosphate. The in vitro release of BP from the implant was evaluated by high-performance liquid chromatography (HPLC). The implants were placed into a scleral pocket in the rabbit's eye. The concentrations of BP in the aqueous humor, vitreous, and retina-choroid were measured by HPLC. The toxicity and biocompatibility of the implant were evaluated by slit lamp examination, electroretinography, and light microscopy.

RESULTS:

In vitro studies demonstrated that the implants released BP in a biphasic pattern for at least 8 weeks. The BP concentrations in the vitreous and the retina-choroid remained within the concentration range capable of suppressing inflammatory responses for more than 8 weeks. The BP concentration was greater in the retina-choroid than in the vitreous. In the aqueous humor, BP was below the detection limit during the observation period. No significant toxicity to the retina was observed. Also, the implant showed good biocompatibility in the eye.

CONCLUSIONS:

These results suggest that the intrascleral implant would be a promising system for delivery of steroid to the posterior segment of the eye.

PMID:
12556407
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center